Wednesday, July 8, 2026

pharma · Congenital Adrenal Hyperplasia · Carcinoid Syndrome · CRNX

Crinetics Pharmaceuticals Europe

Crinetics Pharmaceuticals Europe clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

6055 Lusk Blvd, San Diego, California 92121, US HQ
2008 Founded
597 Employees
Public company Type
CRNX · NYSE Ticker
Company details
Status
Public
HQ
6055 Lusk Blvd, San Diego, California 92121, US
Founded
2008
Employees
597
Programs
12
Drugs
4
Patents
26
Intelligence · Clinical Programs

Crinetics Pharmaceuticals Europe projects

3 ClinicalTrials.gov programs sponsored by Crinetics Pharmaceuticals Europe.

Crinetics Pharmaceuticals Europe has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Atumelnant

    Crinetics Pharmaceuticals Europe GmbH

    Congenital Adrenal Hyperplasia

    phase 3 small molecule active

    2 trials
  2. Paltusotine

    Crinetics Pharmaceuticals Europe GmbH

    Acromegaly

    phase 3 small molecule active

    5 trials
  3. Paltusotine

    Crinetics Pharmaceuticals Europe GmbH

    Carcinoid Syndrome

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Crinetics Pharmaceuticals Europe have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.